This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Zucara Therapeutics, Inc.
Drug Names(s): PRL 2903, PRL2903
PRL-2903 is a somatostatin type 2 (SSTR2) receptors blocker, under development by Zucara therapeutics for the prevention of hypoglycemia in people with diabetes.
The company was founded based on research that these receptors are stimulated at a higher than normal level by over-production of somatostatin in insulin-dependent diabetic patients. The effect of this dysregulated somatostatin on alpha-cells is to suppress glucagon secretion, which results in the insulin-dependent diabetic patient being unable to avoid or recover from hypoglycemia.
Thus, the drug is intended to prevent dangerous low blood sugar by restoring the body's ability to counter-regulate hypoglycemia.
Additional information available to subscribers only: